26
|
Qi W, Li H, Zhang H, Liu S, Wang Y, Gai D, Lu Q, Gan H, Shi Y. Rehabilitation effect of exercise with soft tissue manipulation in patients with lumbar muscle strain. Niger J Clin Pract 2017; 20:629-633. [DOI: 10.4103/njcp.njcp_126_16] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
van den Bent M, Gan H, Reardon DA, Papadopoulos KP, Merrell R, Kumthekar P, Roberts-Rapp L, Holen K, Ansell P, Lassman AB. P06.02 Transcriptional profiling to identify determinants associated with response to ABT-414 in patients with glioblastoma. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now188.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Ameratunga M, McArthur G, Gan H, Cher L. Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma. J Clin Pharm Ther 2016; 41:357-359. [DOI: 10.1111/jcpt.12378] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 02/12/2016] [Indexed: 01/16/2023]
|
29
|
de Guzman J, Gan H. Dural arteriovenous malformation at the right paramedian area of skull base in a 52year old male: a case report. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.1328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
30
|
Van den Bent M, Roberts-Rapp L, Ansell P, Kular R, Song M, Sokolova I, Gan H, Papadopoulos K, Lassman A, Merrell R, Kumthekar P, Scott A, Gomez E, Fischer J, Bhathena A, Holen K, Lai R, Reardon D. 2903 Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31620-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Anderson N, Jackson J, Khoo V, Schneider M, Rolfo M, Gan H, Kaegi K, Sneyd F, Lim Joon D, Wada M. Gross Tumor Volume Size and Oral Cavity Dose Drive Dysphagia in Definitive (Chemo) IMRT for Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
32
|
Gan H, Zheng D, Lei Y, Li S, Zhang Q, Zhou S, Li J, Lin C. Monte Carlo Dose Evaluation for Pancreatic Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Zheng D, Gan H, Zhen W, Lin C, Driewer J, Wahl A, Zhou S. Is PTV Still Appropriate for Prescription Specification in Monte Carlo SBRT Lung Planning? Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
34
|
Zheng S, Wang F, Gan H, Lu J, Jabbour S, Yue N, Zou W. Patient Treatment and Prognosis Information Extraction With Adaptive Self Learning Medical Form Generating System. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
35
|
Li J, Denniston K, Hussain S, Gan H, Lin C. Comparison of CT and MRI-Based Gross Tumor Volume and Organ at Risk Delineation for Pancreatic Cancer Patients Undergoing Neoadjuvant Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1158] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Zhang M, Zhang Q, Gan H, Li S, Zhou S. SU-E-T-360: Stereotactic Radiosurgery Plan Evaluation Using High Order Central Moments. Med Phys 2014. [DOI: 10.1118/1.4888693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
37
|
Caretti V, Noll A, Woo P, Monje M, Cockle J, Bruning-Richardson A, Picton S, Levesley J, Ilett E, Short S, Melcher A, Lawler S, Garzia L, Dubuc A, Pitcher G, Northcott P, Mariampillai A, Mack S, Zayne K, Chan T, Skowron P, Wu X, Lionel A, Morrisy S, Hawkins C, Kongkham P, Rutka J, Huang A, Kenney A, Yang V, Salter M, Taylor M, Garzia L, Morrisy S, Skowron P, Jelveh S, Lindsay P, Largaespada D, Collier L, Dupuy A, Hill R, Taylor M, Hsieh TH, Wang HW, Cheng WC, Wong TT, Huang X, He Y, Dubuc A, Hashizume R, Zhang W, Stehbens S, Younger S, Barshow S, Zhu S, Wu X, Taylor M, Mueller S, Weiss W, James D, Shuman M, Jan YN, Jan L, Marigil M, Jauregi P, Idoate MA, Xipell E, Aldave G, Gonzalez-Huarriz M, Tejada-Solis S, Diez-Valle R, Montero-Carcaboso A, Mora J, Alonso MM, Taylor K, Mackay A, Truffaux N, Morozova O, Butterfield Y, Phillipe C, Vinci M, de Torres C, Cruz O, Mora J, Hargrave D, Monje M, Puget S, Yip S, Jones C, Grill J, Kaul A, Chen YH, Dahiya S, Emnett R, Gianino S, Gutmann D, Miwa T, Oi S, Nonaka Y, Sasaki H, Yoshida K, Lopez E, de Leon AP, Sepulveda C, Zarate L, Diego-Perez J, Pong W, Ding L, McLellan M, Hussain I, Emnett R, Gianino S, Higer S, Leonard J, Guha A, Mardis E, Gutmann D, Sarkar C, Pathak P, Jha P, Purkait S, Sharma V, Sharma MC, Suri V, Faruq M, Mukherjee M, Sivasankaran B, Velayutham RP, Fraschilla IR, Morris KJ, MacDonald TJ, Read TA, Sturm D, Northcott P, Jones D, Korshunov A, Picard D, Lichter P, Huang A, Pfister S, Kool M, Yao TW, Zhang J, Anna B, Brummer T, Gupta N, Nicolaides T, Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James D, Jenkins R, Sarkaria J, Zhang Z. PEDIATRICS LABORATORY RESEARCH. Neuro Oncol 2013. [DOI: 10.1093/neuonc/not186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Anderson N, Jackson J, Wada M, Schneider-Kolsky M, Rolfo M, Gan H, Kaegi K, Sneyd F, Lim Joon D, Khoo V. Creating Guidelines for Reactive and Prophylactic Enteral Feeding in Definitive (Chemo) IMRT for Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Han G, Liu D, Gan H, Li S, Wang Z, Tan W, Zhen W, Hu D. A Dosimetric Study of Intensity Modulated Radiation Therapy for Locally-Advanced Nasopharyngeal Carcinoma With or Without Hippocampal Sparing. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Jackson J, Wada M, Lee S, Gan H, Poon A, Gong S, Gunawardana D, Joon D, Khaw P, Scott A. OC-0325: Pre-Radiotherapy 18Fluoromisonidazole PET Predicts for Long Term Local Control and Survival in Head and Neck Cancer. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)32631-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
41
|
Liew M, Murone C, Walkiewicz M, Mitchell P, Gan H, Barnett S, Russell P, Wright G, Scott A, John T. Correlation of wtEGFR Activation Assessed by mAB806 Binding and EGFR Kinase Mutations in Stage IIIA N2 NSCLC. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34250-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
42
|
Song C, Ma H, Yao C, Tao X, Gan H. Alveolar macrophage-derived vascular endothelial growth factor contributes to allergic airway inflammation in a mouse asthma model. Scand J Immunol 2012; 75:599-605. [PMID: 22324377 DOI: 10.1111/j.1365-3083.2012.02693.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Vascular endothelial growth factor (VEGF) is a potent proangiogenic factor that correlates with vascular permeability and remodelling in asthma. Recently, alveolar macrophages (AM) were shown to be an important source of VEGF during lung injury. Our previous studies demonstrated that AM are an important subset of macrophages in the initiation of asthmatic symptoms. Here, we further investigated whether AM-derived VEGF was required for allergic airway inflammation in asthma. In this study, we reported that the expression of VEGF in AM was significantly increased after allergen challenge. Depleting AM or neutralizing VEGF in alveolus prevented ovalbumin (OVA)-induced asthma-related inflammation by inhibiting the infiltration of inflammatory cells in the lung, reduced the level of the cytokines, IL-4, IL-5, and IL-13, in the bronchoalveolar lavage fluid (BALF) and decreased airway hyperresponsiveness (AHR). Moreover, the inhibition of miR-20b increased the protein level of VEGF in normal AM; conversely, increasing miR-20b in asthmatic AM resulted in decreased VEGF protein levels. These findings suggest that AM-derived VEGF is necessary for allergic airway inflammation in asthmatic mice and miR-20b negatively regulates this expression.
Collapse
|
43
|
Wada M, Chang J, Anderson N, Joon DL, Lee S, Gan H, Khoo V, Scott A. EP-1188 IMPROVING TUMOUR CONTROL IN HYPOXIC HEAD AND NECK CANCERS USING FMISO PET-BASED RADIOTHERAPY DOSE PAINTING. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71521-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Tan V, Tan C, Chow J, Tan K, Lingamanaicker J, Lim V, Tong K, Leong G, Gan H, Goh Y, Lee S, Goh P. OP-016: FEASIBILITY OF STEP DOWN CARE UNIT IN PATIENTS WITH ACUTE ST ELEVATION MYOCARDIAL INFARCTION WHO REMAINED IN KILLIP CLASS 2 VERSUS KILLIP CLASS 1 IMMEDIATE POST SUCCESSFUL PRIMARY PERCUTANEOUS INTERVENTION: SINGLE CENTRE EXPERIENCE. Int J Cardiol 2011. [DOI: 10.1016/s0167-5273(11)70127-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Gan H, Matkovic K, Ammer A, Purgathofer W, Bennett D, Terblanche M. Interactive visual analysis of a large ICU database: a novel approach to data analysis. Crit Care 2011. [PMCID: PMC3061765 DOI: 10.1186/cc9555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
46
|
Gan H, Kakar V, Madhavan B, Clough R, OʼSullivan G. Anaesthetic techniques for thoracic endovascular aortic aneurysm repair (TEVAR): Experience of a large single centre. Eur J Anaesthesiol 2010. [DOI: 10.1097/00003643-201006121-00290] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Leifer ND, Johnson VS, Ben-Ari R, Gan H, Lehnes JM, Guo R, Lu W, Muffoletto BC, Reddy T, Stallworth PE, Greenbaum SG. Solid-State NMR Studies of Chemically Lithiated CF. JOURNAL OF THE ELECTROCHEMICAL SOCIETY 2010; 157:A148-A154. [PMID: 20676233 PMCID: PMC2911803 DOI: 10.1149/1.3267042] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Three types of fluorinated carbon, all in their original form and upon sequential chemical lithiations via n-butyllithium, were investigated by (13)C and (19)F solid-state NMR methods. The three starting CF(x) materials [where x = 1 (nominally)] were fiber based, graphite based, and petroleum coke based. The aim of the current study was to identify, at the atomic/molecular structural level, factors that might account for differences in electrochemical performance among the different kinds of CF(x). Differences were noted in the covalent F character among the starting compounds and in the details of LiF production among the lithiated samples.
Collapse
|
48
|
Le Tourneau C, Michiels S, Gan H, Siu L. Reporting of endpoints and tracking of failures in randomized trials of radiotherapy or concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer (LA-HNSCC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6072 Background: Due to their anatomical complexity, the interactive effects of multiple treatment modalities, the difficulties in differentiating scar tissues versus residual disease and second cancers versus tumor recurrence, LA-HNSCC represent a challenging disease for the reporting of endpoints and the tracking of failures. Methods: We retrieved all randomized trials that began accrual on or after 1978, and enrolled previously untreated nonmetastatic HNSCC patients receiving primary (chemo)radiotherapy. The reporting of endpoints and the tracking of failures in these trials were analyzed. Failures were defined as events meeting a pre-specified endpoint definition. Results: Forty trials involving 13,892 patients fulfilled our inclusion criteria. A total of 125 endpoints were identified: primary versus secondary = 34:91, survival-based (e.g., overall survival [OS]) versus surrogate (e.g. locoregional control [LRC]) = 47:78. In 6 trials, no primary endpoint was identified. LRC and OS accounted for 70% of primary endpoints. All but one trial reported at least one secondary endpoint, with a median of 2 per trial (range: 0–5), and as many as 17 different types of secondary endpoints were reported. Among 72 endpoints tracking locoregional failures, 21/72 (29%) did not define locoregional failure, while 46/72 (64%) specified the absence of complete response as a failure. Whether salvage surgery or elective node dissection was performed or not was reported in less than half of the trials. Furthermore, it was usually not specified if residual disease found during these procedures would account for failure or not. The means (i.e. clinical and/or radiological examinations) to ascertain failures and the protocol-specified timing to track failures were reported in 41% and 67% of surrogate endpoints, respectively. The tracking of other types of failure beyond the first failure is not reported by any of the trials. The reporting of second cancers was found in 15/40 (38%) trials, whereas the duration of follow-up was quantified in 31/40 (78%) trials. Conclusions: These results demonstrate the vast heterogeneity in endpoint reporting and tracking of failures in clinical trials of LA-HNSCC. No significant financial relationships to disclose.
Collapse
|
49
|
Wong E, Lim E, Gan H. 12: The Use of the Laryngeal Tube is Preferred to Endotracheal Intubation in Manikin-Simulated Cardiac Arrest Resuscitations. Ann Emerg Med 2007. [DOI: 10.1016/j.annemergmed.2007.06.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ, Scott AM. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer 2005; 92:1069-77. [PMID: 15770208 PMCID: PMC2361945 DOI: 10.1038/sj.bjc.6602470] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
We report the generation of a chimeric monoclonal antibody (ch806) with specificity for an epitope on the epidermal growth factor receptor (EGFR) that is different from that targeted by all other anti-EGFR therapies. Ch806 antibody is reactive to both de2-7 and overexpressed wild-type (wt) EGFR but not native EGFR expressed in normal tissues at physiological levels. Ch806 was stably expressed in CHO (DHFR −/−) cells and purified for subsequent characterisation and validated for use in preliminary immunotherapy investigations. Ch806 retained the antigen binding specificity and affinity of the murine parental antibody. Furthermore, ch806 displayed enhanced antibody-dependent cellular cytotoxicity against target cells expressing the 806 antigen in the presence of human effector cells. Ch806 was successfully radiolabelled with both iodine-125 and indium-111 without loss of antigen binding affinity or specificity. The radioimmunoconjugates were stable in the presence of human serum at 37°C for up to 9 days and displayed a terminal half-life (T1/2β) of approximately 78 h in nude mice. Biodistribution studies undertaken in BALB/c nude mice bearing de2-7 EGFR-expressing or amplified EGFR-expressing xenografts revealed that 125I-labelled ch806 failed to display any significant tumour retention. However, specific and prolonged tumour localisation of' 111In-labelled ch806 was demonstrated with uptake of 31%ID g−1 and a tumour to blood ratio of 5 : 1 observed at 7 days postinjection. In vivo therapy studies with ch806 demonstrated significant antitumour effects on established de2-7 EGFR xenografts in BALB/c nude mice compared to control, and both murine 806 and the anti-EGFR 528 antibodies. These results support a potential therapeutic role of ch806 in the treatment of suitable EGFR-expressing tumours, and warrants further investigation of the potential of ch806 as a therapeutic agent.
Collapse
|